SCHEMBL13877944

SCHEMBL13877944

COC[C@@]12C=C[C@@](COC)(C[C@](O)(c3ccc(NC(=O)c4nc(C#N)c[nH]4)c(C4=CCC(C)(C)CC4)c3)C1)O2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13877899 0.93 — —
SCHEMBL4231426 0.93 — —
SCHEMBL13877952 0.93 — —
SCHEMBL13877950 0.92 — —
SCHEMBL4231866 0.92 — —
SCHEMBL19264746 0.92 — —
SCHEMBL23808695 0.90 — —
SCHEMBL23808671 0.89 CSF1R (0.48) —
SCHEMBL4238082 0.88 — —
SCHEMBL13877978 0.88 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3208269-B1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2021-09-15 — — EP disclosed
EP-3091006-A1 SULFONYLATION PROCESS USING NONAFLUOROBUTANESULFONYL FLUORIDE Janssen Pharmaceutica N.V. (BE) 2016-11-09 — — EP disclosed
EP-2882744-B1 PROCESS FOR THE PREPARATION OF C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2016-09-21 — — EP disclosed
US-20150232439-A1 PROCESS FOR THE PREPARATION OF C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2015-08-20 — — US disclosed
US-9029352-B2 Process for the preparation of C-FMS kinase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2015-05-12 — — US disclosed
US-20140045789-A1 PROCESS FOR THE PREPARATION OF C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2014-02-13 — — US disclosed
US-8497376-B2 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent JANSSEN PHARMACEUTICA N.V. (BE) 2013-07-30 — — US disclosed
US-8497376-B2 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent JANSSEN PHARMACEUTICA N.V. (BE) 2013-07-30 — — US disclosed
US-20090105296-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2009-04-23 — — US disclosed
US-20090105296-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2009-04-23 — — US disclosed
Send feedback